Results 181 to 190 of about 14,780,830 (367)

Plasma microRNA Signature as Predictive Marker of Clinical Response to Therapy During Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Despite the availability of effective therapies for Multiple Sclerosis (MS), the unpredictable nature of disease progression and the variability in individual treatment outcomes call for reliable biomarkers. This pilot study aims to investigate the potential of plasma circulating microRNAs (miRNAs) as predictive biomarkers for ...
Fortunata Carbone   +19 more
wiley   +1 more source

Searching scale space for activation in PET images [PDF]

open access: green, 1996
Keith J. Worsley   +3 more
openalex   +1 more source

Detecting rs‐fMRI Networks in Disorders of Consciousness: Improving Clinical Interpretability

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Preserved resting‐state functional MRI (rs‐fMRI) networks are typically observed in Disorders of Consciousness (DOC). Despite the widespread use of rs‐fMRI in DOC, a systematic assessment of networks is needed to improve the interpretability of data in clinical practice.
Jean Paul Medina Carrion   +15 more
wiley   +1 more source

Path integration in large-scale space and with novel geometries: Comparing vector addition and encoding-error models. [PDF]

open access: yesPLoS Comput Biol, 2020
Harootonian SK   +4 more
europepmc   +1 more source

TheHubble Space TelescopeExtragalactic Distance Scale Key Project. VII. The Discovery of Cepheids in the Leo I Group Galaxy NGC 3351 [PDF]

open access: bronze, 1997
J. A. Graham   +22 more
openalex   +1 more source

Factors for Rituximab Refractoriness in AQP4‐IgG+ NMOSD: A Cohort Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune condition of the central nervous system (CNS), often associated with aquaporin‐4 antibodies (AQP4‐IgG). Rituximab, a CD20+ B‐cell depleting monoclonal antibody, is widely used as first‐line therapy.
Mariano Marrodan   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy